America First Investment Advisors LLC Grows Position in Johnson & Johnson (NYSE:JNJ)

America First Investment Advisors LLC increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 127,814 shares of the company’s stock after acquiring an additional 1,377 shares during the quarter. Johnson & Johnson comprises 4.0% of America First Investment Advisors LLC’s investment portfolio, making the stock its 16th biggest position. America First Investment Advisors LLC’s holdings in Johnson & Johnson were worth $18,484,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. IFS Advisors LLC raised its stake in Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after purchasing an additional 100 shares during the period. Mountain Hill Investment Partners Corp. acquired a new position in Johnson & Johnson during the fourth quarter worth $29,000. Bay Harbor Wealth Management LLC purchased a new position in Johnson & Johnson during the 4th quarter valued at about $32,000. RPg Family Wealth Advisory LLC purchased a new position in shares of Johnson & Johnson in the third quarter valued at approximately $35,000. Finally, Runnymede Capital Advisors Inc. purchased a new position in Johnson & Johnson in the 4th quarter valued at approximately $38,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $161.14 on Wednesday. The business has a fifty day simple moving average of $157.70 and a 200-day simple moving average of $156.14. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The company has a market cap of $388.32 billion, a P/E ratio of 24.23, a P/E/G ratio of 2.56 and a beta of 0.47. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter in the prior year, the company posted $2.29 EPS. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. Equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were paid a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.08%. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Analysts Set New Price Targets

A number of brokerages recently issued reports on JNJ. Barclays lifted their price target on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Tuesday, January 28th. Leerink Partners decreased their price objective on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Bank of America lifted their target price on Johnson & Johnson from $159.00 to $171.00 and gave the stock a “neutral” rating in a research report on Wednesday, March 5th. Citigroup dropped their price target on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Finally, StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $171.33.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the company’s stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares in the company, valued at $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.